ESTABLISHMENT OF A MODEL OF TRANSPLANTABLE MYELOCYTIC LEUKEMIA (L_(801)) IN LACA MICE

A transplantable myelocytic leukemia model of LACA mice, designated by the name of L_(801), was established by intravenous injection of spleen cell suspension from mice with radiation-induced myclocytic leukemia into mice of the same strain.Until now, for more than three years, the L_(801) has maintained stable and rapid growth and has been reproduced for over 130 serial passages. The incidence of leukemia in inoculated animals was approximately 100% and mean survival time was 10.9±2.1 days. The L_(801) is of myelocytic type which has been determined by cytological, cytochemical, pathological and ultrastructural observations. Its karyotype was hypodiploid, characterized by modal number of 39, loss of Y chromosome and an abnormal huge marker chromosome. The cell cycle duration of the L_(801) was 16 h. C-type viral particles were observed under the electron-microscope. The L_(801) was sensitive, to varying extents, to various anti-tumor agents.We presume that the L_(801) is a useful tool in studies on me     

小鼠可移植性粒细胞白血病瘤株L_(801)的建立

本文用脾细胞悬液给同系成年小鼠尾静脉接种建立起来的小鼠可移植性粒细胞白血病瘤株,命名为L_(801)。三年来已传130余代,瘤株生长稳定,接种成功率接近100%,平均存活时间为10.9± 2.1d.根据细胞学、细胞化学、病理学和超微结构检查,证明本瘤株为粒细胞白血病.白血病细胞染色体检查为亚二倍体,众数为39条,y染色体丢失和存在一个大的标记染色体;细胞周期为16 h;电子显微镜观察可见C型病毒颗粒;对各类抗癌药物均有不同程度的敏感性.因此,L_(801)瘤株的建立将对辐射致癌机理、辐射与病毒致癌之间关系的研究,对抗肿瘤药物筛选和实验肿瘤治疗的研究均有重要意义。     

一些含TMCPDA抗癌铂配合物的研究

本文根据大量的抗癌铂配合物的构效关系研究结果,合成及表征了八种含TMCPDA的新铂配合物(TMCPDA=1,2,2’—三甲基—1,3—环戊二胺),测定了八种配合物对小鼠淋巴白血病L—1210及S—180肉瘤的抑制作用,并研究了配合物的电子结构。结果指出,该系列的配合物有较高的抗癌活性,特别是[Pt(TMCPDA)(Ac—Cl)_2]配合物对L—1210及S—180的抑制作用在此系列配合物中尤为突出。经进一步的临床前的药理研究表明,该配合物的活性较高、毒性较低。配合物的电子结构与抗癌活性的关系的研究结果与以前所得到的抗癌铂配合物的构效关系较一致,表明配合物的电子结构确实与其抗癌活性密切相关。     

顺式-1,3环己二胺合铂配合物的合成、表征及抗癌作用

合成了[Pt(1,3-DACH)X₂](其中1,3-DACH为1,3-环己二胺,X=Cl^-、Br^-、(1/2)O_x^2-、(1/2)mal^2-、AC-CL^-、(1/2)SO₄^2-、NO₃^-)等七种二价铂配合物,并进行了表征,测定了配合物抑制小鼠L-1210白血病及S-180的活性,发现[Pt(1,3-DACH)(AC-Cl)₂〕在此系列中抗癌活性最高,并讨论了配合物的结构与功能的关系。